参考文献/References:
[1].马文韬,樊晓寒,张澍.心房颤动合并心力衰竭的治疗发展方向[J].中国循环杂志,2016,31(11):1142-1144.
[2].刘蕾,张煜,董丽露,等. 老年心力衰竭合并慢性房颤的药物治疗[J].中国老年学杂志,2015,35(8):2293-2296.
[3].中华医学会心血管病学分会心力衰竭学组,中国医师协会心力衰竭专业委员会,中华心血管病杂志编辑委员会,中国心力衰竭诊断和治疗指南2018[J].中华心血管病杂志,2018,46(10):760-789.
[4].Cikes M,Claggett B,Shah AM,et al.Atrial fibrillation in heart failure with preserved ejection fraction：the TOPCAT trial[J].JACC Heart Fail,2018,6(8):619-724.
[5].Goyal P,Almarzooq ZI,Cheung J,et al. Atrial fibrillation and heart failure with preserved ejection fraction:insights on a unique clinical phenotype from a nationally-representative United States cohort[J]. Int J Cardiol,2018,226(1):112-118 .
[6].Patel RB,Vaduganathan M,Shah SJ,et al.Atrial fibrillation in heart failure with preserved ejection fraction:insights into mechanisms and therapeutics[J]. Pharmacol Ther,2017,176(8):32-39 .
[7]. McManus DD,Hsu G,Sung SH,et al. Atrial fibrillation and outcomes in heart failure with preserved versus reduced left ventricular ejection fraction
[8].[J]. J Am Heart Assoc ,2013,2(1):e005694.
[9].Kelly JP,Mentz RJ,Mebazaa A,et al.Patient selection in heart failure with preserved ejection fraction clinical trials[J].J Am Coll Cardiol, 2015,65(16):1668-1682.
[10].Lam CS,Rienstra M,Tay WT,et al. Atrial fibrillation in heart failure with preserved ejection fraction: association with exercise capacity, left ventricular filling pressures, natriuretic peptides, and left atrial volume[J].JACC Heart Fail,2017,5(2):92-98.
[11].Basaraba JE,Barry AR.Pharmacotherapy of heart failure with preserved ejection fraction[J]. Pharmacotherapy,2015,35(4):351-360 .
[12].Kaye DM,Silvestry FE,Gustafsson F,et al. Impact of atrial fibrillation on rest and exercise haemodynamics in heart failure with mid-range and preserved ejection fraction[J]. Eur J Heart Fail,2017 ,19(12):1690-1697.
[13].Bracey A, Shatila W, Wilson J.Bleeding in patients receiving non-vitamin K oral anticoagulants:clinical trial evidence[J].Ther Adv Cardiovasc Dis,2018,12(12):361-380.
[14].Santhanakrishnan R, Wang N, Larson MG,et al. Atrial fibrillation begets heart failure and vice versa temporal associations and differences in preserved versus reduced ejection fraction[J].Circulation,2016,133(5):484-492.
[15].Machino-Ohtsuka T,Seo Y,Ishizu T,et al. Efficacy,safety,and outcomes of catheter ablation of atrial fibrillation in patients with heart failure with preserved ejection fraction[J]. J Am Coll Cardiol ,2013,62(20):1857-1865.
[16].Kotecha D,Lam CS,van Veldhuisen DJ,et al. Heart failure with preserved ejection fraction and atrial fibrillation：vicious twins[J]. J Am Coll Cardiol,2016,68(20):2217-2228 .
[17].Santos AB,Kraigher-Krainer E,Gupta DK,et al. Impaired left atrial function in heart failure with preserved ejection fraction[J]. European Journal of Heart Failure,2014,16(10):1096 -1103.
[18].Zafrir B,Lund LH,Laroche C,et al.Prognostic implications of atrial fibrillation in heart failure with reduced, mid-range, and preserved ejection fraction: a report from 14 964 patients in the European Society of Cardiology Heart Failure Long-Term Registry[J]. Eur Heart J,2018 ,39(48):4277-4284.
[19].左易霞,范晋奇,殷跃辉. 射血分数保留的心力衰竭新进展 [J]. 心血管病学进展,2017,38(1):21-24.
[20].黄从新,张澍,黄德嘉,等. 心房颤动:目前的认识和治疗的建议-2018[J].中国心脏起搏与心电生理杂志,2018,32(4):315-368.
[21].DeVore AD,Piccini JP.Mineralocorticoid receptor antagonism for the treatment of AF and HFpEF: preserving hope[J].JACC Heart Fail,2018,6(8):698-700.
[22].O’Neal WT,Sandesara P,Hammadah M,et al. Gender Differences in the risk of adverse outcomes in patients with atrial fibrillation and heart failure with preserved ejection fraction[J]. Am J Cardiol ,2017,119(11):1785-1790.
[23].Sartipy U,Dahlstr?m U,Fu M,et al. Atrial fibrillation in heart failure with preserved, mid-range, and reduced ejection fraction[J].JACC Heart Fail,2017,5(8):565-575.
[24].Hohendanner F,Heinzel FR,Blaschke F,et al. Pathophysiological and therapeutic implications in patients with atrial fibrillation and heart failure[J]. Heart Fail Rev,2018,23(1):27-36 .
[25].January CT, Wann LS, Calkins H, et al. 2019 AHA/ACC/HRS focused update of the 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation [J]. Circulation ,2019,139:1-49.
[26].Llàcer P,Nú?ez J,Bayés-Genís A,et al.Digoxin and prognosis of heart failure in older patients with preserved ejection fraction:importance of heart rate. Results from an observational and multicenter study[J]. Eur J Intern Med,2019,60(2):18-23 .
[27].Black-Maier E,Ren X,Steinberg BA,et al. Catheter ablation of atrial fibrillation in patients with heart failure and preserved ejection fraction[J].Heart Rhythm,2018,15(5):651-657.
[28].刘少稳.心房颤动的认识和治疗进展[J].上海医学,2014,37(3):191-195.
[29].孙姣,孙源君,尹晓盟,等. 心房颤动合并心力衰竭患者导管消融治疗与药物治疗预后对比[J]. 辽宁医学杂志,2018,32(2):3-6.
相似文献/References:
[1]贺鹏康,周菁.心房颤动治疗新技术——冷冻球囊消融[J].心血管病学进展,2016,(1):1.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.001]
HE Pengkang,ZHOU Jing.Cryoballoon Ablation, A Novel Technology for Atrial Fibrillation Treatment[J].Advances in Cardiovascular Diseases,2016,(5):1.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.001]
[2]都明辉,施海峰*,佟佳宾,等.心房颤动消融相关性无症状性脑缺血[J].心血管病学进展,2016,(1):3.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.002]
DU Minghui,SHI Haifeng*,TONG Jiabin,et al.Silent Cerebral Ischemia Related to Atrial Fibrillation Ablation[J].Advances in Cardiovascular Diseases,2016,(5):3.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.002]
[3]郑环杰,综述,肖骅,等.心房颤动抗栓治疗研究进展[J].心血管病学进展,2016,(2):142.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.012]
ZHENG Huanjie,XIAO Hua.Progress of Antithrombotic Therapy in Patients with Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2016,(5):142.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.012]
[4]张清,综述,罗素新,等.新型Xa 因子抑制剂———依度沙班在心房颤动患者抗凝治疗中的研究进展[J].心血管病学进展,2016,(2):151.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.014]
ZHANG Qing,LUO Suxin,TANG Jiong.Novel Factor Xa Inhibitors—Edoxaban in Prevention of Stroke in
Patients with Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2016,(5):151.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.014]
[5]胡红玲,综述,罗素新,等.预防非瓣膜性心房颤动性脑卒中的治疗新进展[J].心血管病学进展,2016,(3):250.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.009]
HU Hongling,LUO Suxin.New Progress in the Treatment for Cerebral Apoplexy of Nonvalvular
Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2016,(5):250.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.009]
[6]王超,杨国澍,综述,等.关附甲素治疗心房颤动的研究进展[J].心血管病学进展,2016,(3):254.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.010]
WANG Chao,YANG Guoshu,CAI Lin,et al.Research Progress of the Treatment of Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2016,(5):254.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.010]
[7]徐小东,综述,杨东辉,等.决奈达隆治疗心房颤动的现状及展望[J].心血管病学进展,2016,(4):368.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.011]
XU Xiaodong,YANG Donghui.Status and Prospect of Dronedarone in Treating Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2016,(5):368.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.011]
[8]张莎,储国俊,吴弘.经导管左心耳封堵术的临床应用进展[J].心血管病学进展,2015,(5):547.[doi:10.3969/j.issn.1004-3934.2015.05.006]
ZHANG Sha,CHU Guojun,WU Hong.Clinial Application Advances in Left Atrial Appendage Closure[J].Advances in Cardiovascular Diseases,2015,(5):547.[doi:10.3969/j.issn.1004-3934.2015.05.006]
[9]汪俊,杨浩.心房颤动射频消融的术式演变[J].心血管病学进展,2015,(5):574.[doi:10.3969/j.issn.1004-3934.2015.05.013]
WANG Jun,YANG Hao.Evolution of Radiofrequency Ablation of Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2015,(5):574.[doi:10.3969/j.issn.1004-3934.2015.05.013]
[10]赵璐,苏立.心房颤动与离子通道重构研究进展[J].心血管病学进展,2015,(5):580.[doi:10.3969/j.issn.1004-3934.2015.05.014]
ZHAO Lu,SU Li.Research Progress of Atrial Fibrillation and Ion Channel Remodeling[J].Advances in Cardiovascular Diseases,2015,(5):580.[doi:10.3969/j.issn.1004-3934.2015.05.014]